Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $191.6 million.

  • Amylyx Pharmaceuticals' Cash from Financing Activities rose 23940750.0% to $191.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.3 million, marking a year-over-year increase of 5488867.52%. This contributed to the annual value of $348000.0 for FY2024, which is 9017.78% down from last year.
  • Amylyx Pharmaceuticals' Cash from Financing Activities amounted to $191.6 million in Q3 2025, which was up 23940750.0% from -$31000.0 recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Cash from Financing Activities high stood at $232.2 million for Q4 2022, and its period low was -$1.1 million during Q4 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $964500.0 (2023), whereas its average is $47.3 million.
  • The largest annual percentage gain for Amylyx Pharmaceuticals' Cash from Financing Activities in the last 5 years was 23940750.0% (2025), contrasted with its biggest fall of 21481.48% (2025).
  • Over the past 5 years, Amylyx Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$1.1 million in 2021, then surged by 21899.25% to $232.2 million in 2022, then plummeted by 99.9% to $230000.0 in 2023, then crashed by 52.17% to $110000.0 in 2024, then soared by 174087.27% to $191.6 million in 2025.
  • Its last three reported values are $191.6 million in Q3 2025, -$31000.0 for Q2 2025, and $65.7 million during Q1 2025.